CardieX Yönetim

Yönetim kriter kontrolleri 3/4

CardieX CEO'su Craig Cooper, Dec2017 tarihinde atandı, in görev süresi 6.92 yıldır. in toplam yıllık tazminatı A$ 1.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 83.4% maaş ve 16.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.1% ine doğrudan sahiptir ve bu hisseler A$ 357.19K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 6.3 yıldır.

Anahtar bilgiler

Craig Cooper

İcra Kurulu Başkanı

AU$1.1m

Toplam tazminat

CEO maaş yüzdesi	83.4%
CEO görev süresi	6.9yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Craig Cooper'un ücretlendirmesi CardieX'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$1m	AU$946k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$8m
Dec 31 2023	n/a	n/a	-AU$9m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$1m	AU$772k	-AU$19m
Mar 31 2023	n/a	n/a	-AU$16m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$13m
Jun 30 2022	AU$1m	AU$608k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$11m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$1m	AU$529k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$911k	AU$447k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$851k	AU$419k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$392k	AU$226k	-AU$3m

Tazminat ve Piyasa: Craig 'nin toplam tazminatı ($USD 738.73K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 298.55K ).

Tazminat ve Kazançlar: Craig 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Craig Cooper (61 yo)

6.9yrs

Görev süresi

AU$1,134,097

Tazminat

Mr. Craig R. Cooper, BEc., LLB (Hons), is the Co-Owner at C2 Ventures Pty Ltd. He is Co-Founder, Group CEO, MD & Executive Director of CardieX Limited. He was Co-Founder, CEO, MD & Executive Director of Ca...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niall Charles Cairns	Co-Founder & Executive Chairman	6.9yrs	AU$488.43k	0.66% A$ 213.1k
Craig Cooper	Co-Founder	6.9yrs	AU$1.13m	1.1% A$ 357.2k
Ahmad Qasem	Chief Science & Research Officer	no data	AU$240.19k	0.0084% A$ 2.7k
Douglas Kurschinski	Executive VP & Head of Global Sales for AtCor Medical Division	no data	AU$360.84k	Veri yok
Mark Gorelick	Chief Product Officer	3.9yrs	AU$395.47k	0.038% A$ 12.1k
Catherine Liao	Chief Strategy Officer	2.2yrs	AU$385.31k	0% A$ 0
Sanjeev Bhavnani	Chief Clinical Officer	less than a year	Veri yok	Veri yok
Louisa Ho	Company Secretary	1.4yrs	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: CDX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Niall Charles Cairns	Co-Founder & Executive Chairman	6.9yrs	AU$488.43k	0.66% A$ 213.1k
Craig Cooper	Co-Founder	6.9yrs	AU$1.13m	1.1% A$ 357.2k
Randall Nelson	Independent Non-Executive Director	9yrs	AU$85.08k	0.0052% A$ 1.7k
Harry Kim	Special Advisor	5.7yrs	Veri yok	Veri yok
Alberto Avolio	Member of Medical Advisory Board	no data	Veri yok	Veri yok
John Cockcroft	Member of Medical Advisory Board	2.4yrs	Veri yok	Veri yok
Charlie Taylor	Independent Non-Executive Director	less than a year	AU$24.14k	Veri yok

6.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CDX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

CardieX Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CardieX Limited, Annual General Meeting, Nov 29, 2024

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

Recent updates

New minor risk - Share price stability

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş